METTL7B: A Potential Drug Target and Biomarker (G196410)

Target Name: METTL7B

NCBI ID: G196410

METTL7B

METTL7B: A Potential Drug Target and Biomarker

METTL7B, also known as METTL7A, is a gene that encodes a protein involved in the regulation of microRNA (miRNA) levels in the human body. MiRNA is a small non-coding RNA molecule that plays a crucial role in post-transcriptional gene regulation by guiding the translation of specific mRNAs into protein. aberrant miRNA levels have been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, targeting miRNA regulation by METTL7B is a promising strategy for the development of new therapeutic approaches.

The METTL7B gene was first identified in the human genomic sequence as a potential drug target due to its involvement in the regulation of miRNA levels. The METTL7B protein has been shown to interact with several known miRNA-regulating proteins, including miR-18a, miR-202, and miR-204, which are involved in the regulation of various cellular processes, including cell growth, apoptosis, and transcriptional regulation.

In addition to its potential as a drug target, METTL7B has also been identified as a potential biomarker for various diseases. The METTL7B gene has been shown to be downregulated in various cancer types, including breast, ovarian, and colorectal cancer. This suggests that METTL7B may be a useful biomarker for the diagnosis and prognosis of these cancers. Moreover, studies have shown that METTL7B levels are also reduced in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, which further supports its potential as a biomarker for these conditions.

The potential drug target status of METTL7B is further supported by its role in the regulation of miRNA levels. METTL7B has been shown to physically interact with the miR-202 protein, which is a known regulator of miRNA levels. The METTL7B-miR-202 interaction has been shown to play a role in the regulation of cellular processes, including cell growth, apoptosis, and transcriptional regulation. This interaction suggests that METTL7B may be a potential drug target by inhibiting the activity of miR-202, which would result in increased miRNA levels and potentially leading to the regulation of cellular processes that are disrupted in various diseases.

In conclusion, METTL7B is a promising drug target and biomarker due to its involvement in the regulation of miRNA levels and its potential role in the development of various diseases. Further research is needed to fully understand the mechanisms of METTL7B's role in miRNA regulation and its potential as a drug and biomarker. However, the potential of METTL7B as a drug target and biomarker is a promising area of research that could lead to new therapeutic approaches for the treatment of various diseases.

Protein Name: Methyltransferase Like 7B

Functions: Thiol S-methyltransferase that catalyzes the transfer of a methyl group from S-adenosyl-l-methionine to hydrogen sulfide and other thiol compounds including dithiothreitol, 7alpha-thiospironolactone, L-penicillamine, and captopril

The "METTL7B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about METTL7B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets